Docality.com Logo
 
Dr. Jonathan  Fleischmann  Md image

Dr. Jonathan Fleischmann Md

2510 Westchester Ave Suite A
Bronx NY 10461
718 173-3030
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 189333
NPI: 1174539605
Taxonomy Codes:
208800000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

None Found

Publications

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
To evaluate the role of adjuvant interferon alfa after complete resection of locally extensive renal cell carcinoma.A total of 283 eligible patients with pT3-4a and/or node-positive disease were randomly assigned after radical nephrectomy and lymphadenectomy to observation or to interferon alfa-NL (Wellferon, Burroughs-Wellcome, Research Park, NC) given daily for 5 days every 3 weeks for up to 12 cycles. Patients were stratified on the basis of pathologic stage. Patients remained on treatment until documented recurrence, excessive toxicity, or patient/physician preference deemed removal appropriate.At median follow-up of 10.4 years, median survival was 7.4 years in the observation arm and 5.1 year in the treatment arm (log-rank P =.09). Median recurrence-free survival was 3.0 years in the observation arm and 2.2 years in the interferon arm (P =.33). Performance status (P =.003), nodal status (N2 v N0, P <.0001), and tumor stage (P =.0002) were significant prognostic factors in multivariate analysis. A proportional hazards model examining the effects of treatment arm and time to recurrence on survival after recurrence among patients who recurred found that random assignment to interferon treatment (P =.009) and shorter time to recurrence (P <.0001) were independent predictors of shorter survival after recurrence. Although no lethal toxicities were observed, severe (grade 4) toxicities including neutropenia, myalgia, fatigue, depression, and other neurologic toxicities occurred in 11.4% of those randomly assigned to interferon treatment.Adjuvant treatment with interferon did not contribute to survival or relapse-free survival in this group of patients.

Map & Directions

2510 Westchester Ave Suite A Bronx, NY 10461
View Directions In Google Maps

Nearby Doctors

1400 Pelham Pkwy S
Bronx, NY 10461
718 183-3060
1400 Pelham Pkwy S Jacobi Medical Center Building 1 9E4
Bronx, NY 10461
718 186-6817
2809 Middletown Rd
Bronx, NY 10461
718 978-8800
1400 Pelham Pkwy S Room 5C15
Bronx, NY 10461
718 184-4589
Weiler - Emergency Medicine 1825 Eastchester Road
Bronx, NY 10461
718 043-3333
1400 Pelham Pkwy S Dept. Of Emergency Medicine, Jacobi Medical Center
Bronx, NY 10461
718 185-5820
1825 Eastchester Rd
Bronx, NY 10461
718 042-2767
1400 Pelham Pkwy S Dpmt Of Internal Medicine, Jacobi Medical Ctr
Bronx, NY 10461
718 185-5000
2917 Bruckner Blvd
Bronx, NY 10461
718 977-7888
1300 Morris Park Ave Belfer Building, Suite 501
Bronx, NY 10461
718 043-3317